# Endocrine / Vitamin Watchlist originals (2026-05-10) Preservation archive created before consolidating the calcium/PTH/D/K2/thyroid cluster. --- ## Original: topics/calcium-parathyroid-vitamin-d.md ```markdown --- topic: Calcium, Parathyroid Hormone, and Vitamin D Axis tags: [calcium, PTH, parathyroid, vitamin-D, vitamin-K2, hypercalcemia, vascular-calcification, supplementation] priority: monitor last_updated: 2026-05-03 confidence: medium-high abstract: >- The calcium/PTH/D pattern is still a monitoring issue, not a parathyroid alarm: total calcium is high-normal and stable, PTH normalized after vitamin-D repletion, and 25(OH)D is already sufficient. The decision is to avoid pushing D higher, use same-day calcium + albumin + PTH + 25(OH)D if rechecking the axis, and keep Lp(a)-valve surveillance owned by echocardiography rather than by K2 speculation. open_questions: - Can Biomed or another local lab provide ionized calcium if total calcium crosses range or PTH rises again? - Does baseline echocardiography show any Lp(a)-linked aortic valve sclerosis/stenosis? --- # Calcium, Parathyroid Hormone, and Vitamin D Axis ## Summary This branch does not currently look like primary hyperparathyroidism or vitamin-D toxicity. The useful interpretation is narrower: - total calcium has been high-normal for years, with one older 2.55 mmol/L value in 2015 and recent values around 2.47-2.50 mmol/L; - albumin has sometimes been high, which can push total calcium up without proving high ionized calcium; - PTH was elevated once in 2022 with only modest vitamin-D status, then normalized by 2024; - 25(OH)D is now about 105 nmol/L, already sufficient and below the range where toxicity concern starts. So the action is maintenance and periodic paired-axis checking, not supplement escalation. ## Decision pathway | Situation | Interpretation | Action | |---|---|---| | Calcium remains in range and PTH normal | Stable high-normal total calcium; no active parathyroid diagnosis | Keep D3 maintenance, monitor with routine chemistry | | Calcium is repeatedly above range or corrected/ionized calcium is high | Hypercalcemia branch opens | Repeat calcium + albumin/corrected calcium + PTH + creatinine/eGFR + phosphorus + 25(OH)D; clinician review | | PTH rises while calcium is normal | Could be secondary hyperparathyroidism or normocalcemic PHPT only after exclusions | Repeat PTH over 3-6 months and exclude low D, kidney disease, malabsorption, hypercalciuria, and medication causes | | 25(OH)D rises above ~125 nmol/L or calcium rises with D dosing | Too much D becomes plausible | Reduce/hold D3 and recheck calcium/PTH/25(OH)D with clinician input | | Concern is Lp(a)-aortic valve risk | This is not answered by calcium or K2 labs | Baseline echocardiogram; CAC/CCTA answer coronary plaque, not valve reassurance | ## What to do now - Keep vitamin D in maintenance mode; do not chase levels higher than the current sufficient range. - If the axis is rechecked, draw the paired set on the same day: calcium, albumin, PTH, 25(OH)D, phosphorus, creatinine/eGFR. Ionized calcium is useful if available, but Biomed's public tariff lists serum calcium, albumin, phosphorus, PTH/iPTH, and 25(OH)D; it did not show ionized calcium or vitamin K on the 2026-05-03 tariff scrape. - Treat aortic-valve surveillance as an Lp(a) imaging issue: baseline echo first; K2 is not a substitute. - K2 label/form verification is fine for supplement hygiene, but repeat serum vitamin K is low priority unless a clinician is specifically checking deficiency or malabsorption. ## Evidence / context The 2022 Fifth International Workshop PHPT guideline frames primary hyperparathyroidism around elevated adjusted or ionized calcium with inappropriately high PTH, and normocalcemic PHPT requires repeatedly normal adjusted and ionized calcium with elevated PTH after secondary causes are excluded. That makes the current pattern mostly reassuring unless calcium or PTH changes. Vitamin-D guidance is also conservative. NIH ODS lists 25(OH)D >=50 nmol/L as adequate for most people and notes possible adverse associations above 125 nmol/L, especially above 150 nmol/L. The 2024 Endocrine Society prevention guideline argues against routine extra vitamin-D supplementation/testing for generally healthy adults aged 50-74 without a specific indication. In this profile, testing exists because the axis was previously abnormal, but the conclusion is still not to push D upward. Vitamin K2 has a plausible matrix-Gla-protein/calcification mechanism, but outcome evidence remains weak. A 2023 RCT meta-analysis suggested modest CAC slowing, while dialysis-focused RCT meta-analysis and the AVADEC aortic-valve trial did not show reliable clinical or calcification-score benefit. K2 can stay as a modest supplement choice; it should not be framed as proven protection against Lp(a)-related valve or coronary disease. ## References - PMID: 36245251 — 2022 Fifth International Workshop PHPT evaluation/management guideline. - NIH ODS Vitamin D fact sheet, updated 2025: adequacy >=50 nmol/L; potential adverse effects above 125 nmol/L. - PMID: 38828931 — 2024 Endocrine Society vitamin D prevention guideline. - PMID: 37252246 and PMID: 38046003 — vitamin K vascular-calcification RCT meta-analyses with mixed/limited outcome evidence. - PMID: 35465686 — AVADEC vitamin K2 + D aortic-valve calcification RCT, neutral for valve/coronary calcification progression. - PMID: 37650693 — Lp(a) is causally linked to calcific aortic valve disease; Lp(a)-lowering impact on valve disease remains unproven. ``` --- ## Original: topics/vitamin-d-k2.md ```markdown --- topic: Vitamin D and K2 tags: [supplements, vitamins, bone-health, cardiovascular] priority: important last_updated: 2026-05-03 confidence: high abstract: >- Vitamin D is already sufficient, so the practical goal is consistency and avoiding excess. The current NOW product provides D3 plus MK-4 K2; switching to MK-7 is optional supplement tidying, not a cardiovascular treatment. Calcium/PTH monitoring and echo/CAC/CCTA decisions matter more than chasing higher D or K2 numbers. related_topics: [lp-a, calcium-parathyroid-vitamin-d.md, recommended-supplement-adjustments.md] open_questions: - Is there any reason to change K2 form after the supplement stack is simplified? --- # Vitamin D and K2 ## Bottom line 25(OH)D is already in a sufficient range. The current NOW product is 1,000 IU vitamin D3 + 45 mcg vitamin K2 as menaquinone-4 (MK-4) per capsule, so 2 capsules/day gives 2,000 IU D3 + 90 mcg MK-4. ## Practical interpretation | Question | Current call | |---|---| | More D3? | No default escalation. Maintain consistency and recheck only as part of the calcium/PTH axis. | | MK-4 vs MK-7? | Label accuracy matters; switching to MK-7 is optional, not urgent. | | K2 for Lp(a)/valves/CAC? | Mechanistically plausible, but not proven event or valve protection. Do not let it distract from echo, BP, ApoB/Lp(a) management, smoking cessation, or imaging. | | Serum vitamin K repeat? | Low priority unless deficiency/malabsorption or clinician-directed monitoring becomes the question. | ## Evidence / context NIH ODS treats >=50 nmol/L 25(OH)D as adequate for most people and flags possible adverse associations above 125 nmol/L. The 2024 Endocrine Society prevention guideline does not support routine extra vitamin-D supplementation for generally healthy adults aged 50-74 without a specific indication. For K2, trial evidence is mixed: meta-analysis suggests possible modest CAC slowing, but the 2022 AVADEC valve-calcification RCT and dialysis-focused meta-analysis do not establish reliable clinical protection. ## References / verification - NOW Foods Vitamin D3 & K2 product page: https://www.nowfoods.com/products/supplements/vitamin-d3-k2-capsules - NIH ODS Vitamin D fact sheet: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/ - PMID: 38828931 — 2024 Endocrine Society vitamin D prevention guideline. - PMID: 37252246, PMID: 35465686, PMID: 38046003 — vitamin K/calcification evidence. ``` --- ## Original: topics/tsh-thyroid-trend.md ```markdown --- topic: TSH Thyroid Trend tags: [thyroid, tsh, cardiovascular-risk, statins, lipid, lp(a), monitoring, subclinical-hypothyroidism, TPO-antibodies] priority: important last_updated: 2026-05-04 confidence: high abstract: >- The April 2026 TSH normalization broke the earlier upward-thyroid-drift story. Thyroid remains a watchlist item, not a current explanatory center; repeat TSH/free T4/TPO is useful only if the signal recurs or symptoms become more specific. related_topics: [lp-a.md, recommended-supplement-adjustments.md] open_questions: [Was the Dec 2025 rise to 3.61 transient/lab-noise/reversible rather than true thyroid drift? Does TPO antibody testing still add enough value to justify doing it once higher-priority GI work settles?] --- # TSH Thyroid Trend Analysis ## Profile Summary The old KB framing treated the thyroid trend as a steadily rising near-hypothyroid trajectory. The April 2026 result broke that pattern. TSH moved from 1.5 (2015) / 1.4 (2018) / 2.0 (2024-08) / 2.65 (2025-10) / 2.82 (2025-11) / 3.61 (2025-12) back down to **1.75 (2026-04)**. Free T4 has historically been normal. Atorvastatin was reduced from 40 mg to 20 mg in Oct 2025. ## 1. What changed ### The monotonic-rise story is no longer valid The December 2025 result made it look as if TSH was climbing toward subclinical hypothyroidism. That is no longer the cleanest interpretation because the latest value normalized. The correct frame now is: - there was a temporary high-normal spike to 3.61 - the thyroid axis is **not currently showing persistent upward drift** - immediate escalation to a thyroid workup is no longer high priority This does **not** prove the thyroid is irrelevant. It means the KB should stop treating thyroid drift as an active problem until the signal recurs. ## 2. Statins and thyroid — still background context, not a current conclusion Statin-thyroid interaction remains biologically plausible and was one reason to watch the trend. The April 2026 normalization is at least compatible with the idea that the prior higher reading was reversible rather than a durable thyroid-failure trajectory. For Dag specifically: - long exposure to atorvastatin kept the question alive - dose reduction from 40 mg to 20 mg happened before the normalization - the newest result is therefore more reassuring than the KB previously allowed But the evidence is still too weak to say "atorvastatin caused the TSH rise." The clean statement is simply that the concerning trend was not confirmed. ## 3. Lp(a) connection — still true in principle, but not actionable from this round The general point still holds: true hypothyroidism or persistent subclinical hypothyroidism can worsen Lp(a)-related risk and can raise atherogenic markers. That matters conceptually in a high-Lp(a) profile. What changed is the action threshold: - when TSH was 3.61 and climbing, early thyroid workup looked attractive - with TSH back at 1.75, there is no current evidence that thyroid dysfunction is materially amplifying the Lp(a) problem right now So the thyroid-Lp(a) link remains background physiology, not an active explanation for the current risk picture. ## 4. Does TPO antibody testing still make sense? ### Best current answer: optional, not urgent TPO antibodies are still the best way to detect latent autoimmune thyroid disease. But the reason to order them weakened sharply after the normalization. Current framing: - **If the goal is completeness / future-proofing:** TPO antibodies are reasonable once the more urgent GI / hematology questions settle. - **If the goal is prioritization:** TPO antibodies are no longer near the front of the queue. That is the main KB correction. The previous version over-promoted thyroid workup relative to the evidence now available. ## 5. Monitoring plan ### What makes sense now 1. **Do not rush repeat thyroid testing in a few days or weeks** — low yield after a normalizing result. 2. **Recheck TSH with routine follow-up bloodwork**, not as a separate urgent branch. 3. **Add Free T4 / TPO only if one of these happens:** - TSH rises again toward or above ~4.0 - symptoms suggest hypothyroidism strongly enough to matter clinically - you want to close the autoimmune-thyroid question once the higher-priority branches are finished ## 6. Key Takeaways 1. **The old "steady upward TSH trend" framing is broken by the April 2026 result.** 2. **TSH 1.75 is reassuring** and downgrades thyroid from active concern to background monitoring. 3. **The statin-thyroid interaction remains plausible but unproven** — normalization fits a reversible signal better than progressive thyroid failure. 4. **TPO antibodies are now optional rather than urgent.** 5. **The thyroid-Lp(a) link still matters conceptually, but this round does not support thyroid dysfunction as a current risk amplifier.** ## Research Trace - Preserved action boundary: December 2025 raised concern; April 2026 removed the urgency. - Keep TSH on routine monitoring, but do not treat it as an active escalation branch unless the signal returns. - Guideline anchor added after external audit: NICE NG145, Thyroid disease: assessment and management, supports symptom/context-driven thyroid testing and monitoring rather than treating one normalized TSH fluctuation as an active diagnosis: https://www.nice.org.uk/guidance/ng145 ```